Citation & Authors
JAMA Netw Open. 2025;8(7):e2521016.
ABSTRACT · RESEARCH SUMMARY
Research summary
The study matched 30,430 patients per group with type 2 diabetes and obesity to compare semaglutide/tirzepatide with other glucose-lowering drugs. Over up to 7 years, dementia (HR 0.63; 95% CI 0.50–0.81), stroke, and death were less frequent, while Parkinson’s disease and intracerebral hemorrhage did not differ significantly. The findings suggest potential neurovascular benefits that require confirmation in trials.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
